$CANB Stephen Medina Joins Canbiola, Inc. Corporate Advisory BoardPress Release | 02/01/2019
HICKSVILLE, NY, Feb. 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canbiola, Inc. (OTCQB: CANB), is pleased to announce that Steven Medina Esq. has joined its Corporate Advisory Board. The purpose of the Advisory Board is to assist and advise the Board of Directors and Executive team’s effort in growing Canbiola fiscally and in a socially responsible manner.
Mr. Medina is a well-recognized and seasoned healthcare professional in corporate compliance. His specific knowledge of the Medicare, Medicaid and HIPAA regulatory environment makes him uniquely qualified to provide infrastructure and support in such key and critical areas as operations, revenue cycle, management, and ancillary provider contracts. Professionally Mr. Medina brings his expertise into service to oversee and monitor healthcare compliance program implementation, developing, coordinating and participation in compliance training program that focuses on the essential elements of the medical field compliance programs. Mr. Medina has held training programs for both employees and physicians to better understand and comply with pertinent federal and state statues as well as regulations and standards. Mr. Medina is often called upon to review and revise corporate compliance programs in light of changes in the needs of the practice or changes in the law. Mr. Medina also develops a solid audit procedure for both private and publicly traded companies that establishes a consistent methodology for selecting and examining records to serve as a basis for future audits.
Mr. Medina is a graduate of the class of 1984 from Queens College and a graduate of the class of 1987 from St. John’s University School of Law. He is currently the founder of Accutus Consulting Group, Inc. which was formed to assist physicians and other providers in understanding the complex healthcare industry.
Mr. Medina states that “I am extremely excited and looking forward to working with Canbiola to consult on business strategy, sales, marketing, product plans and identifying additional new market opportunities in this field involving new cannabinoid-based products.”
Canbiola is a manufacturer of proprietary non-psychoactive cannabinoid products, CBD, extracted from the hemp plant. We are focused on the commercial development of hemp and CBD-based products for both the medical and consumer market. Our product line includes hemp oil drops (of various concentrations), muscle and joint salves, and production of its new CBD CryoGel pain relief product. All products are non-opioid-based, all natural and organic compound products that contain 99.9% pure CBD and are THC free.
According to Canbiola’s CEO Marco Alfonsi, "Having Mr. Medina join as our newest member of the corporate Advisory Board speaks volumes to our ongoing efforts to remain in compliance in the medical regulatory environment.” Mr. Alfonsi added, "Mr. Medina also adds a unique dimension to the recent launch of our Duramed Division specifically targeting the medical reimbursement opportunities for our medical device pain and wellness products. We believe that Mr. Medina will facilitate the opening of doors for potential opportunities in his medical compliance practice relationships for Canbiola that would not otherwise be available to us.” Alfonsi concluded, “This is a very exciting time in the Company’s focus upon broadening our reach and horizons via professionals like Mr. Medina.”
About Canbiola, Inc.:
Canbiola, Inc. is a public company trading under symbol CANB.
Canbiola, Inc. is a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola has developed its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states, but pure CBD products are legal in all 50 states. The company has already launched several products found at www.canbiola.com.
CONTACT INFORMATION:
HICKSVILLE, NY, Feb. 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canbiola, Inc. (OTCQB: CANB), is pleased to announce that Steven Medina Esq. has joined its Corporate Advisory Board. The purpose of the Advisory Board is to assist and advise the Board of Directors and Executive team’s effort in growing Canbiola fiscally and in a socially responsible manner.
Mr. Medina is a well-recognized and seasoned healthcare professional in corporate compliance. His specific knowledge of the Medicare, Medicaid and HIPAA regulatory environment makes him uniquely qualified to provide infrastructure and support in such key and critical areas as operations, revenue cycle, management, and ancillary provider contracts. Professionally Mr. Medina brings his expertise into service to oversee and monitor healthcare compliance program implementation, developing, coordinating and participation in compliance training program that focuses on the essential elements of the medical field compliance programs. Mr. Medina has held training programs for both employees and physicians to better understand and comply with pertinent federal and state statues as well as regulations and standards. Mr. Medina is often called upon to review and revise corporate compliance programs in light of changes in the needs of the practice or changes in the law. Mr. Medina also develops a solid audit procedure for both private and publicly traded companies that establishes a consistent methodology for selecting and examining records to serve as a basis for future audits.
Mr. Medina is a graduate of the class of 1984 from Queens College and a graduate of the class of 1987 from St. John’s University School of Law. He is currently the founder of Accutus Consulting Group, Inc. which was formed to assist physicians and other providers in understanding the complex healthcare industry.
Mr. Medina states that “I am extremely excited and looking forward to working with Canbiola to consult on business strategy, sales, marketing, product plans and identifying additional new market opportunities in this field involving new cannabinoid-based products.”
Canbiola is a manufacturer of proprietary non-psychoactive cannabinoid products, CBD, extracted from the hemp plant. We are focused on the commercial development of hemp and CBD-based products for both the medical and consumer market. Our product line includes hemp oil drops (of various concentrations), muscle and joint salves, and production of its new CBD CryoGel pain relief product. All products are non-opioid-based, all natural and organic compound products that contain 99.9% pure CBD and are THC free.
According to Canbiola’s CEO Marco Alfonsi, "Having Mr. Medina join as our newest member of the corporate Advisory Board speaks volumes to our ongoing efforts to remain in compliance in the medical regulatory environment.” Mr. Alfonsi added, "Mr. Medina also adds a unique dimension to the recent launch of our Duramed Division specifically targeting the medical reimbursement opportunities for our medical device pain and wellness products. We believe that Mr. Medina will facilitate the opening of doors for potential opportunities in his medical compliance practice relationships for Canbiola that would not otherwise be available to us.” Alfonsi concluded, “This is a very exciting time in the Company’s focus upon broadening our reach and horizons via professionals like Mr. Medina.”
About Canbiola, Inc.:
Canbiola, Inc. is a public company trading under symbol CANB.
Canbiola, Inc. is a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola has developed its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states, but pure CBD products are legal in all 50 states. The company has already launched several products found at www.canbiola.com.
CONTACT INFORMATION:
